The newest generation of GLP-1 drugs are being hailed by some as “miracle drugs” for the treatment of obesity. But GLP-1s are expensive, insurance coverage is limited, and not everyone with obesity can and or wants to take them. In this episode, which is based on Goldman Sachs Research’s latest Top of Mind report, obesity medicine physician Dr. Fatima Cody Stanford and Jonathan Gruber, professor of economics and chairman of the Economics Department at MIT, discuss how large the addressable market for GLP-1s actually is and the implications for US fiscal health.
If you want more insights from Goldman Sachs, make sure to visit GS.com and sign up for Briefings, a weekly newsletter from Goldman Sachs about trends spanning markets, industries, and the global economy.
Does Human Behavior Move the Markets?
What is Alternative Risk Premia and Why are Investors Excited About It?
Is Womenomics Working?
What's the Business Case for Investing in America's Low-Income Communities?
Why Do Smaller Companies Receive Higher Valuations for New Initiatives?
What's Keeping Insurers Up at Night?
Why Are Savings Rates Back in Focus in the UK?
What's the Role of Private Capital Markets in Europe?
What's Next For Emerging Markets?
How is Tech Reshaping the City Skyline?
Why ESG is Becoming a 'Business Imperative' for Asset Managers
With Brexit Uncertainty and Sluggish Growth, Where Are European Investors Seeking Value?
What Can Credit Markets Tell Us About the Chances of a US Recession?
France in Focus: CEOs Playing Offense and Defense
Tech in Europe: Innovating Amidst Constraints
China's 'Bumpy Deceleration'
The Scene from China: VC and Tech Reach New Scale
Commodities Outlook: Return of the New Oil Order
Tech Talk 2019
Founders' Spotlight: What It's Really Like to Start and Scale a Business
Create your
podcast in
minutes
It is Free
TED Radio Hour
FT Alphachat
Freakonomics Radio
Odd Lots
Slate Money